1
|
Griguolo G, Miglietta F, Paré L, Generali DG, Frassoldati A, Musolino A, Spazzapan S, Vernaci G, Giarratano T, Mele ML, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Schiavi F, Pinato C, Prat A, Guarneri V, Dieci MV. Abstract P4-02-13: Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p4-02-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Background: Hormone-receptor (HR)+/HER2- breast cancer (BC) is a biologically heterogeneous disease. Homologous recombination deficiency (HRD) and BRCA mutations have been previously reported to be associated with worse outcomes in HR+/HER2- metastatic BC patients receiving CDK4/6 inhibitors and endocrine therapy. Here, we assess the relation between HRD and RB-loss signatures, intrinsic subtyping, the PAM50-based chemo-endocrine score, and response to chemotherapy-based therapy and endocrine treatment in HR+/HER2- early BC. Methods: GIADA is a multicentric neoadjuvant phase II trial that treated premenopausal patients with Luminal B (LumB)-like BC (HR-positive, HER2-negative, with Ki67>20% and/or histologic Grade 3) with a combination of chemotherapy, immunotherapy and endocrine treatment. Expression of 758 genes on baseline tumor samples from all 43 patients was quantified by nCounter platform. The LETLOB phase II trial randomized postmenopausal women with clinical stage II-IIIA HR+/HER2- BC to neoadjuvant letrozole + lapatinib or letrozole + placebo for 6 months (Guarneri, JCO 2014). Gene-expression data (Affymetrix platform) from pre-treatment frozen core-biopsies was available from 66 out of 92 pts enrolled. Intrinsic subtype was assigned using a research-based PAM50 subtype predictor. A published HRD signature (Peng, Nat Commun 2014) and a signature of RB loss (RBsig), previously reported to potentially predict resistance to CDK4/6 inhibitors in HR+/HER2- BC (Malorni, Oncotarget 2016) were computed. The PAM50 based chemo-endocrine score (CES) was calculated using published definition (Prat, CCR 2017). Higher values of CES indicate increased endocrine sensitivity, while lower values indicate chemosensitivity. Association between genomic signatures was assessed through Pearson’s correlation coefficient. Association of genomic signatures with pCR was assessed through logistic regression and association with PEPI scores was assessed through Kruskal-Wallis test. Results: HRD signature levels were significantly higher in non-luminal (Basal-like and HER2-enriched) tumors as compared to Luminal (A or B) tumors (p>0.001 in the GIADA trial, p=0.021 in the LETLOB trial). Moreover, higher levels of HRD signature were associated with higher levels of RB-loss signature (Pearson correlation 0.355, p=0.020 in the GIADA trial; Pearson correlation 0.942, p< 0.001 in the LETLOB trial), higher levels of Basal-like signature (Pearson correlation 0.502, p< 0.001 in the GIADA trial; Pearson correlation 0.373, p=0.002 in the LETLOB trial) and lower levels of CES (Pearson correlation -0.422, p=0.005 in the GIADA trial; Pearson correlation -0.763, p< 0.001 in the LETLOB trial), indicative of higher chemosensitivity. In the GIADA trial, higher levels of HRD signature (p=0.018) and RBloss signature (p=0.073) and lower levels of CES (p=0.007) were associated with higher pCR rates after chemo, endocrine and immunotherapy. In the LETLOB trial, lower levels of HRD signature (p=0.068) and RBloss signature (p=0.042) and higher levels of CES (p=0.050) were associated with higher sensitivity to endocrine treatment (lower PEPI scores, 0 vs 1-3 vs 4 or more, after neoadjuvant letrozole). Conclusions: In HR+/HER2- early BC, HRD gene signatures, RB-loss gene signatures and non-luminal (especially Basal-like) intrinsic subtyping are associated with each other and associated with higher sensitivity to chemotherapy-based therapy and lower sensitivity to endocrine treatment. These observations might help correctly tailor systemic therapy, including biologic agents, in patients with HR+/HER2- early and advanced BC.
Citation Format: Gaia Griguolo, Federica Miglietta, Laia Paré, Daniele G. Generali, Antonio Frassoldati, Antonino Musolino, Simon Spazzapan, Grazia Vernaci, Tommaso Giarratano, Marcello Lo Mele, Giancarlo Bisagni, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Francesca Schiavi, Claudia Pinato, Aleix Prat, Valentina Guarneri, Maria Vittoria Dieci. Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-02-13.
Collapse
Affiliation(s)
- Gaia Griguolo
- 1Department of Surgery, Oncology and Gastroenterology, University of Padua; Division of Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Federica Miglietta
- 2Department of Surgery, Oncology and Gastroenterology, University of Padua; Division of Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Italy
| | - Laia Paré
- 3Reveal Genomics, Barcelona, Catalonia, Spain
| | | | | | | | - Simon Spazzapan
- 7Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
| | - Grazia Vernaci
- 8Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS
| | - Tommaso Giarratano
- 9Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | | | | | | | - Enrico Tagliafico
- 13University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy
| | - Katia Cagossi
- 14Ospedale Bernardino Ramazzini, Carpi, Carpi, Emilia-Romagna, Italy
| | | | | | | | - Valentina Guarneri
- 18Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| | | |
Collapse
|
2
|
Dieci MV, Guarneri V, Tosi A, Bisagni G, Musolino A, Spazzapan S, Moretti G, Vernaci GM, Griguolo G, Giarratano T, Urso L, Schiavi F, Pinato C, Magni G, Lo Mele M, De Salvo GL, Rosato A, Conte P. Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Clin Cancer Res 2022; 28:308-317. [PMID: 34667023 PMCID: PMC9401542 DOI: 10.1158/1078-0432.ccr-21-2260] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 08/31/2021] [Accepted: 10/12/2021] [Indexed: 01/07/2023]
Abstract
PURPOSE The role of immunotherapy in hormone receptor (HR)-positive, HER2-negative breast cancer is underexplored. PATIENTS AND METHODS The neoadjuvant phase II GIADA trial (NCT04659551, EUDRACT 2016-004665-10) enrolled stage II-IIIA premenopausal patients with Luminal B (LumB)-like breast cancer (HR-positive/HER2-negative, Ki67 ≥ 20%, and/or histologic grade 3). Patients received: three 21-day cycles of epirubicin/cyclophosphamide followed by eight 14-day cycles of nivolumab, triptorelin started concomitantly to chemotherapy, and exemestane started concomitantly to nivolumab. Primary endpoint was pathologic complete response (pCR; ypT0/is, ypN0). RESULTS A pCR was achieved by 7/43 patients [16.3%; 95% confidence interval (CI), 7.4-34.9]; the rate of residual cancer burden class 0-I was 25.6%. pCR rate was significantly higher for patients with PAM50 Basal breast cancer (4/8, 50%) as compared with other subtypes (LumA 9.1%; LumB 8.3%; P = 0.017). Tumor-infiltrating lymphocytes (TIL), immune-related gene-expression signatures, and specific immune cell subpopulations by multiplex immunofluorescence were significantly associated with pCR. A combined score of Basal subtype and TILs had an AUC of 0.95 (95% CI, 0.89-1.00) for pCR prediction. According to multiplex immunofluorescence, a switch to a more immune-activated tumor microenvironment occurred following exposure to anthracyclines. Most common grade ≥3 treatment-related adverse events (AE) during nivolumab were γ-glutamyltransferase (16.7%), alanine aminotransferase (16.7%), and aspartate aminotransferase (9.5%) increase. Most common immune-related AEs were endocrinopathies (all grades 1-2; including adrenal insufficiency, n = 1). CONCLUSIONS Luminal B-like breast cancers with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti-PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context.
Collapse
Affiliation(s)
- Maria Vittoria Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.,Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.,Corresponding Author: Maria Vittoria Dieci, Department of Surgery, Oncology and Gastroenterology - University of Padova, Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padova, Italy. Phone: 3904-9821-5295; Fax: 3904-9821-5932; E-mail:
| | - Valentina Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.,Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Anna Tosi
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
| | - Giancarlo Bisagni
- Department of Oncology and Advanced Technologies, Oncology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy
| | - Antonino Musolino
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.,Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Simon Spazzapan
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Gabriella Moretti
- Department of Oncology and Advanced Technologies, Oncology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy
| | - Grazia Maria Vernaci
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.,Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Gaia Griguolo
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.,Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Tommaso Giarratano
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Loredana Urso
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
| | - Francesca Schiavi
- UOSD Hereditary Tumors, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Claudia Pinato
- UOSD Hereditary Tumors, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Giovanna Magni
- Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Marcello Lo Mele
- Department of Pathology, Azienda Ospedale Università Padova, Padova, Italy
| | - Gian Luca De Salvo
- Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Antonio Rosato
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.,Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Pierfranco Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.,Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| |
Collapse
|
3
|
Corallo D, Zanon C, Pantile M, Tonini GP, Zin A, Francescato S, Rossi B, Trevisson E, Pinato C, Monferrer E, Noguera R, Aliño SF, Herrero MJ, Biffi A, Viscardi E, Aveic S. Integrated CGH/WES Analyses Advance Understanding of Aggressive Neuroblastoma Evolution: A Case Study. Cells 2021; 10:2695. [PMID: 34685674 PMCID: PMC8534916 DOI: 10.3390/cells10102695] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2021] [Revised: 10/04/2021] [Accepted: 10/06/2021] [Indexed: 01/03/2023] Open
Abstract
Neuroblastoma (NB) is the most common extra-cranial malignancy in preschool children. To portray the genetic landscape of an overly aggressive NB leading to a rapid clinical progression of the disease, tumor DNA collected pre- and post-treatment has been analyzed. Array comparative genomic hybridization (aCGH), whole-exome sequencing (WES), and pharmacogenetics approaches, respectively, have identified relevant copy number alterations (CNAs), single nucleotide variants (SNVs), and polymorphisms (SNPs) that were then combined into an integrated analysis. Spontaneously formed 3D tumoroids obtained from the recurrent mass have also been characterized. The results prove the power of combining CNAs, SNVs, and SNPs analyses to assess clonal evolution during the disease progression by evidencing multiple clones at disease onset and dynamic genomic alterations during therapy administration. The proposed molecular and cytogenetic integrated analysis empowers the disease follow-up and the prediction of tumor recurrence.
Collapse
Affiliation(s)
- Diana Corallo
- Laboratory of Target Discovery and Biology of Neuroblastoma, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, C.so Stati Uniti 4, 35127 Padova, Italy; (D.C.); (M.P.); (G.P.T.)
| | - Carlo Zanon
- Bioinformatics Core Service, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, C.so Stati Uniti 4, 35127 Padova, Italy;
| | - Marcella Pantile
- Laboratory of Target Discovery and Biology of Neuroblastoma, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, C.so Stati Uniti 4, 35127 Padova, Italy; (D.C.); (M.P.); (G.P.T.)
| | - Gian Paolo Tonini
- Laboratory of Target Discovery and Biology of Neuroblastoma, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, C.so Stati Uniti 4, 35127 Padova, Italy; (D.C.); (M.P.); (G.P.T.)
| | - Angelica Zin
- Advanced Diagnostics and Target Discovery in Rare Pediatric Solid Tumors, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, C.so Stati Uniti 4, 35127 Padova, Italy;
- Pediatric Hematology, Oncology, and Stem Cell Transplant Center, Department of Woman’s and Child’s Health, University of Padova, Via Gustiniani 3, 35128 Padova, Italy; (S.F.); (B.R.); (A.B.); (E.V.)
| | - Samuela Francescato
- Pediatric Hematology, Oncology, and Stem Cell Transplant Center, Department of Woman’s and Child’s Health, University of Padova, Via Gustiniani 3, 35128 Padova, Italy; (S.F.); (B.R.); (A.B.); (E.V.)
| | - Bartolomeo Rossi
- Pediatric Hematology, Oncology, and Stem Cell Transplant Center, Department of Woman’s and Child’s Health, University of Padova, Via Gustiniani 3, 35128 Padova, Italy; (S.F.); (B.R.); (A.B.); (E.V.)
| | - Eva Trevisson
- Clinical Genetics Unit, Department of Woman’s and Child’s Health, University of Padova, Via Gustiniani 3, 35128 Padova, Italy; (E.T.); (C.P.)
| | - Claudia Pinato
- Clinical Genetics Unit, Department of Woman’s and Child’s Health, University of Padova, Via Gustiniani 3, 35128 Padova, Italy; (E.T.); (C.P.)
| | - Ezequiel Monferrer
- Pathology Department, Medical School, University of Valencia-INCLIVA, 46010 Valencia, Spain; (E.M.); (R.N.)
| | - Rosa Noguera
- Pathology Department, Medical School, University of Valencia-INCLIVA, 46010 Valencia, Spain; (E.M.); (R.N.)
| | - Salvador F. Aliño
- Pharmacogenetics Unit, Instituto Investigación Sanitaria La Fe and Department Pharmacology, University of Valencia, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain; (S.F.A.); (M.J.H.)
| | - Maria Jose Herrero
- Pharmacogenetics Unit, Instituto Investigación Sanitaria La Fe and Department Pharmacology, University of Valencia, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain; (S.F.A.); (M.J.H.)
| | - Alessandra Biffi
- Pediatric Hematology, Oncology, and Stem Cell Transplant Center, Department of Woman’s and Child’s Health, University of Padova, Via Gustiniani 3, 35128 Padova, Italy; (S.F.); (B.R.); (A.B.); (E.V.)
| | - Elisabetta Viscardi
- Pediatric Hematology, Oncology, and Stem Cell Transplant Center, Department of Woman’s and Child’s Health, University of Padova, Via Gustiniani 3, 35128 Padova, Italy; (S.F.); (B.R.); (A.B.); (E.V.)
| | - Sanja Aveic
- Laboratory of Target Discovery and Biology of Neuroblastoma, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, C.so Stati Uniti 4, 35127 Padova, Italy; (D.C.); (M.P.); (G.P.T.)
- Department of Dental Materials and Biomaterials Research, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074 Aachen, Germany
| |
Collapse
|
4
|
Dieci M, Griguolo G, Bisagni G, Musolino A, Spazzapan S, Moretti G, Schiavi F, Pinato C, Vernaci G, Giarratano T, Urso L, Tosi A, Magni G, Lo Mele M, De Salvo G, Rosato A, Guarneri V, Conte P. 129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Buja A, Vianello FA, Zaccagnini F, Pinato C, Maculan P. Health issues in female Moldovan migrants in a north-eastern Italian region. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Migration from Eastern Europe to Italy is still massively expanding, with a subsequent increase of migrants in the job market who are traditionally employed in low specialized and high strain jobs. In this context Health Literacy is a known factor contributing to immigrant health disparities. The purpose of this study was to evaluate the health status of a population of migrant Moldovan women and their access to health care services in northern Italy by age class and health literacy level.
Methods
We administered an ad-hoc questionnaire to adult Moldovan women to assess their lifestyles, employment status, reported health status, access to Health Services and Health Literacy. Moreover, the study compared our data with a sample of Italian women of the same age range living in North-Eastern region interviewed in 2015. Analysis employs descriptive statistics.
Results
The sample included 170 Moldovan women (age 46.5 ±12.3). Prevalence of active smokers was found double in women with a low Health Literacy. Health Literacy status also determined the different access to Public Health Services, with women with higher literacy using more programmed health services and screening programs, and women with lower literacy conversely using more emergency health services. Overall reported health status was found worse in our sample than in Italian women and reported disease prevalence among age ranges was different than Italian ones with an increased probability for allergies, lumbar diseases and depression.
Conclusions
Some diseases have a higher prevalence in Moldovan than in Italian women. Health literacy is associated with lifestyles and use of health care services also in migrants, as previously demonstrated for native population.
Key messages
Tailored prevention programs and intervention should be designed in Moldovan women to address high prevalence diseases in this population. Strategy to improve health literacy should involve immigrants. Some diseases resulted well-spread over the whole sample and not influenced by age or employment; the difficulties migrants have to overcome might influence their health status.
Collapse
Affiliation(s)
- A Buja
- Cardiologic-Thoracic-Vascular Sciences and Public Health, University of Padova, Padua, Italy
| | - F A Vianello
- Philosophy, Sociology, Pedagogy and Applied Psychology, University of Padova, Padua, Italy
| | - F Zaccagnini
- Philosophy, Sociology, Pedagogy and Applied Psychology, University of Padova, Padua, Italy
| | - C Pinato
- Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - P Maculan
- Cardiologic-Thoracic-Vascular Sciences and Public Health, University of Padova, Padua, Italy
| |
Collapse
|
6
|
Collantoni E, Solmi M, Gallicchio D, Santonastaso P, Meneguzzo P, Carvalho AF, Stubbs B, Clementi M, Pinato C, Forzan M, Cassina M, Fontana F, Piva I, Siani R, Salvo P, Tenconi E, Veronese N, Correll CU, Favaro A. Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism and Eating Disorders: Data From a New Biobank and Meta-Analysis of Previously Published Studies. Eur Eat Disord Rev 2018; 25:524-532. [PMID: 29057600 DOI: 10.1002/erv.2555] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Revised: 08/22/2017] [Accepted: 08/22/2017] [Indexed: 12/18/2022]
Abstract
OBJECTIVES We investigated whether catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with eating disorders (EDs). METHODS We conducted a systematic literature search of studies published until 15 January 2017 and added data from the Italian 'Biobanca Veneta per i Disturbi Alimentari' biobank, performing a meta-analysis comparing COMT Val158Met genotype and allele frequencies in EDs and anorexia nervosa (AN) or bulimia nervosa (BN) patients versus controls. RESULTS Ten studies plus Biobanca Veneta per i Disturbi Alimentari (ED: n = 920, controls: n = 261 controls) with 3541 ED patients (AN = 2388; BN = 233) and 3684 controls were included. There were no significant group differences in COMT Val158Met alleles and genotype frequencies between patients and controls, for all EDs pooled together [range of odds ratios (ORs): 0.96-1.04, p-values: 0.46-0.97, I2 = 0%] and when analysing separately patients with AN (ORs: 0.94-1.04, p-values: 0.31-0.61, I2 = 0%) or BN (ORs: 0.80-1.09, p-values: 0.28-0.64, I2 = 0-44%). CONCLUSIONS Meta-analysing data results from 11 studies and 7225 subjects show that COMT Val158Met polymorphism is not associated with EDs. Copyright © 2017 John Wiley & Sons, Ltd and Eating Disorders Association.
Collapse
Affiliation(s)
- Enrico Collantoni
- Neuroscience Department, University of Padua, Italy
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
| | - Marco Solmi
- Neuroscience Department, University of Padua, Italy
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
| | - Davide Gallicchio
- Neuroscience Department, University of Padua, Italy
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
| | - Paolo Santonastaso
- Neuroscience Department, University of Padua, Italy
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
- Centro Neuroscienze Cognitive (CNC), University of Padua, Italy
| | - Paolo Meneguzzo
- Neuroscience Department, University of Padua, Italy
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
| | - Andrè F Carvalho
- Translational Psychiatry Research Group, Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Brazil
| | - Brendon Stubbs
- Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK
- Physiotherapy Department, South London and Maudsley NHS Foundation Trust, UK
- Faculty of Health, Social Care and Education, Anglia Ruskin University, UK
| | - Maurizio Clementi
- Clinical Genetics Unit, Department of Woman and Child Health, University of Padua, Italy
| | - Claudia Pinato
- Clinical Genetics Unit, Department of Woman and Child Health, University of Padua, Italy
| | - Monica Forzan
- Clinical Genetics Unit, Department of Woman and Child Health, University of Padua, Italy
| | - Matteo Cassina
- Clinical Genetics Unit, Department of Woman and Child Health, University of Padua, Italy
| | - Francesca Fontana
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
| | - Ivana Piva
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
| | - Roberta Siani
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
| | - Pierandrea Salvo
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
| | - Elena Tenconi
- Neuroscience Department, University of Padua, Italy
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
- Centro Neuroscienze Cognitive (CNC), University of Padua, Italy
| | | | - Christoph U Correll
- Department of Psychiatry Research, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY, USA
- Department of Psychiatry and Molecular Medicine Hempstead, Hofstra Northwell School of Medicine, Hempstead, NY, USA
| | - Angela Favaro
- Neuroscience Department, University of Padua, Italy
- BIO.VEDA Group (Biobanca Veneta per i Disturbi dell'Alimentazione: Biobank of the Veneto Region Eating Disorders Units), Italy
- Centro Neuroscienze Cognitive (CNC), University of Padua, Italy
| |
Collapse
|
7
|
Solmi M, Gallicchio D, Collantoni E, Correll CU, Clementi M, Pinato C, Forzan M, Cassina M, Fontana F, Giannunzio V, Piva I, Siani R, Salvo P, Santonastaso P, Tenconi E, Veronese N, Favaro A. Serotonin transporter gene polymorphism in eating disorders: Data from a new biobank and META-analysis of previous studies. World J Biol Psychiatry 2016; 17:244-57. [PMID: 26895183 DOI: 10.3109/15622975.2015.1126675] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
UNLABELLED Objectives Growing interest focuses on the association between 5-HTTLPR polymorphism and eating disorders (ED), but published findings have been conflicting. Methods The Italian BIO.VE.D.A. biobank provided 976 samples (735 ED patients and 241 controls) for genotyping. We conducted a literature search of studies published up to 1 April 2015, including studies reporting on 5HTTLPR genotype and allele frequencies in obesity and/or ED. We ran a meta-analysis, including data from BIO.VE.D.A. - comparing low and high-functioning genotype and allele frequencies in ED vs. CONTROLS Results Data from 21 studies, plus BIO.VE.D.A., were extracted providing information from 3,736 patients and 2,707 controls. Neither low- nor high-functioning genotype frequencies in ED patients, with both bi- and tri-allelic models, differed from controls. Furthermore, neither low- nor high-functioning allele frequencies in ED or in BN, in both bi- and triallelic models, differed from control groups. After sensitivity analysis, results were the same in AN vs. CONTROLS Results remained unaltered when investigating recessive and dominant models. Conclusions 5HTTLPR does not seem to be associated with ED in general, or with AN or BN in particular. Future studies in ED should explore the role of ethnicity and psychiatric comorbidity as a possible source of bias.
Collapse
Affiliation(s)
- M Solmi
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy ;,g Department of Neuroscience , University of Padova , Italy
| | - D Gallicchio
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy ;,g Department of Neuroscience , University of Padova , Italy
| | - E Collantoni
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy ;,g Department of Neuroscience , University of Padova , Italy
| | - C U Correll
- c The Zucker Hillside Hospital, Psychiatry Research, NorthShore - Long Island Jewish Health System , Glen Oaks , New York , USA ;,d Hofstra North Shore LIJ School of Medicine , Hempstead , New York , USA ;,e The Feinstein Institute for Medical Research , Manhasset , New York , USA ;,f Albert Einstein College of Medicine , Bronx , New York , USA
| | - M Clementi
- h Clinical Genetics Unit, Department of Woman and Child Health , University of Padova
| | - C Pinato
- h Clinical Genetics Unit, Department of Woman and Child Health , University of Padova
| | - M Forzan
- h Clinical Genetics Unit, Department of Woman and Child Health , University of Padova
| | - M Cassina
- h Clinical Genetics Unit, Department of Woman and Child Health , University of Padova
| | - F Fontana
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy
| | - V Giannunzio
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy ;,g Department of Neuroscience , University of Padova , Italy
| | - I Piva
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy
| | - R Siani
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy
| | - P Salvo
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy
| | - P Santonastaso
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy ;,g Department of Neuroscience , University of Padova , Italy ;,i Centro Neuroscience Cognitive (CNC), University of Padova , Italy
| | - E Tenconi
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy ;,g Department of Neuroscience , University of Padova , Italy ;,i Centro Neuroscience Cognitive (CNC), University of Padova , Italy
| | - N Veronese
- b Department of Medicine- DIMED , Geriatrics Section, University of Padova , Italy
| | - A Favaro
- a BIO.VE.D.A. Group (BIObanca VEneta per I Disturbi Dell'alimentazione: Biobank of the Veneto Region Eating Disorders Units) , Veneto Region , Italy ;,g Department of Neuroscience , University of Padova , Italy ;,i Centro Neuroscience Cognitive (CNC), University of Padova , Italy
| |
Collapse
|
8
|
Collantoni E, Michelon S, Tenconi E, Degortes D, Titton F, Manara R, Clementi M, Pinato C, Forzan M, Cassina M, Santonastaso P, Favaro A. Functional connectivity correlates of response inhibition impairment in anorexia nervosa. Psychiatry Res Neuroimaging 2016; 247:9-16. [PMID: 26655584 DOI: 10.1016/j.pscychresns.2015.11.008] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2015] [Revised: 10/12/2015] [Accepted: 11/30/2015] [Indexed: 01/12/2023]
Abstract
Anorexia nervosa (AN) is a disorder characterized by high levels of cognitive control and behavioral perseveration. The present study aims at exploring inhibitory control abilities and their functional connectivity correlates in patients with AN. Inhibitory control - an executive function that allows the realization of adaptive behavior according to environmental contingencies - has been assessed by means of the Stop-Signal paradigm. The study involved 155 patients with lifetime AN and 102 healthy women. A subsample underwent resting-state functional magnetic resonance imaging and was genotyped for COMT and 5-HTTLPR polymorphisms. AN patients showed an impaired response inhibition and a disruption of the functional connectivity of the ventral attention circuit, a neural network implicated in behavioral response when a stimulus occurs unexpected. The 5-HTTLPR genotype appears to significantly interact with the functional connectivity of ventral attention network in explaining task performance in both patients and controls, suggesting a role of the serotoninergic system in mechanisms of response selection. The disruption of the ventral attention network in patients with AN suggests lower efficiency of bottom-up signal filtering, which might be involved in difficulties to adapt behavioral responses to environmental needs. Our findings deserve further research to confirm their scientific and therapeutic implications.
Collapse
Affiliation(s)
- Enrico Collantoni
- Psychiatric Clinic, Department of Neurosciences, University of Padova, Via Giustiniani 3, 35128 Padova, Italy
| | - Silvia Michelon
- Psychiatric Clinic, Department of Neurosciences, University of Padova, Via Giustiniani 3, 35128 Padova, Italy
| | - Elena Tenconi
- Psychiatric Clinic, Department of Neurosciences, University of Padova, Via Giustiniani 3, 35128 Padova, Italy
| | - Daniela Degortes
- Psychiatric Clinic, Department of Neurosciences, University of Padova, Via Giustiniani 3, 35128 Padova, Italy
| | - Francesca Titton
- Psychiatric Clinic, Department of Neurosciences, University of Padova, Via Giustiniani 3, 35128 Padova, Italy
| | - Renzo Manara
- Department of Medicine and Surgery, University of Salerno, Italy; IRCCS Istituto San Camillo, Venezia, Italy
| | - Maurizio Clementi
- Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Italy
| | - Claudia Pinato
- Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Italy
| | - Monica Forzan
- Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Italy
| | - Matteo Cassina
- Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Italy
| | - Paolo Santonastaso
- Psychiatric Clinic, Department of Neurosciences, University of Padova, Via Giustiniani 3, 35128 Padova, Italy
| | - Angela Favaro
- Psychiatric Clinic, Department of Neurosciences, University of Padova, Via Giustiniani 3, 35128 Padova, Italy.
| |
Collapse
|
9
|
Tenconi E, Degortes D, Clementi M, Collantoni E, Pinato C, Forzan M, Cassina M, Santonastaso P, Favaro A. Clinical and genetic correlates of decision making in anorexia nervosa. J Clin Exp Neuropsychol 2015; 38:327-37. [DOI: 10.1080/13803395.2015.1112878] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|